PL2595960T3 - Sól i solwaty pochodnej tetrahydroizochinoliny - Google Patents

Sól i solwaty pochodnej tetrahydroizochinoliny

Info

Publication number
PL2595960T3
PL2595960T3 PL11740973.0T PL11740973T PL2595960T3 PL 2595960 T3 PL2595960 T3 PL 2595960T3 PL 11740973 T PL11740973 T PL 11740973T PL 2595960 T3 PL2595960 T3 PL 2595960T3
Authority
PL
Poland
Prior art keywords
solvates
salt
tetrahydroisoquinoline derivative
tetrahydroisoquinoline
derivative
Prior art date
Application number
PL11740973.0T
Other languages
English (en)
Inventor
Thomas David Mccarthy
Peter Michael Kelly
Craig James Stewart Boyle
Alexander Redvers Eberlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2595960T3 publication Critical patent/PL2595960T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11740973.0T 2010-07-21 2011-07-21 Sól i solwaty pochodnej tetrahydroizochinoliny PL2595960T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36636710P 2010-07-21 2010-07-21

Publications (1)

Publication Number Publication Date
PL2595960T3 true PL2595960T3 (pl) 2016-09-30

Family

ID=44386640

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11740973.0T PL2595960T3 (pl) 2010-07-21 2011-07-21 Sól i solwaty pochodnej tetrahydroizochinoliny

Country Status (19)

Country Link
US (3) US8614227B2 (pl)
EP (2) EP2595960B1 (pl)
JP (3) JP5948326B2 (pl)
CN (2) CN105777636A (pl)
AU (3) AU2011281381B2 (pl)
CA (1) CA2803699C (pl)
DK (1) DK2595960T3 (pl)
ES (1) ES2570135T3 (pl)
HK (1) HK1224290A1 (pl)
HR (1) HRP20160540T1 (pl)
HU (1) HUE028620T2 (pl)
ME (1) ME02407B (pl)
NZ (2) NZ605444A (pl)
PL (1) PL2595960T3 (pl)
PT (1) PT2595960E (pl)
SI (1) SI2595960T1 (pl)
SM (1) SMT201600171B (pl)
WO (1) WO2012010843A1 (pl)
ZA (1) ZA201300169B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028620T2 (en) * 2010-07-21 2016-12-28 Novartis Ag Tetrahydroisoquinoline derivative salt and solvates
US9320530B2 (en) * 2013-03-13 2016-04-26 The Spectranetics Corporation Assisted cutting balloon
WO2015003223A1 (en) * 2013-07-08 2015-01-15 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods of their use
PL3245198T3 (pl) 2015-01-13 2020-10-05 Novartis Ag Pochodne pirolidyny jako antagonisty angiotensyny ii typu 2
PT3268356T (pt) 2015-03-12 2021-11-23 Novartis Ag Compostos heterocíclicos e métodos para a sua utilização
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
WO2018001997A1 (en) 2016-06-27 2018-01-04 Ratiopharm Gmbh Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
JP2019514862A (ja) * 2017-03-23 2019-06-06 ノバルティス アーゲー (s)−2−(ジフェニルアセチル)−1,2,3,4−テトラヒドロ−6−メトキシ−5−(フェニルメトキシ)−3−イソキノリンカルボン酸ナトリウムの無水結晶形
KR102132761B1 (ko) 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
WO2020013951A1 (en) * 2018-07-12 2020-01-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
AU747110B2 (en) * 1998-02-25 2002-05-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
EP1830869B1 (en) 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
AU2007229322B2 (en) * 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
JP6232184B2 (ja) * 2010-01-19 2017-11-15 ノバルティス アーゲー 神経伝導速度改善のための方法および組成物
HUE028620T2 (en) * 2010-07-21 2016-12-28 Novartis Ag Tetrahydroisoquinoline derivative salt and solvates

Also Published As

Publication number Publication date
US9162985B2 (en) 2015-10-20
US20120022101A1 (en) 2012-01-26
NZ708529A (en) 2016-11-25
PT2595960E (pt) 2016-06-02
ME02407B (me) 2016-09-20
EP3081557A1 (en) 2016-10-19
EP2595960A1 (en) 2013-05-29
ZA201300169B (en) 2016-03-30
JP2013531057A (ja) 2013-08-01
AU2011281381B2 (en) 2015-07-16
US8614227B2 (en) 2013-12-24
AU2017203236A1 (en) 2017-06-08
JP2016164178A (ja) 2016-09-08
CN105777636A (zh) 2016-07-20
US20140080865A1 (en) 2014-03-20
AU2015238774A1 (en) 2015-10-29
CA2803699A1 (en) 2012-01-26
US20150105422A1 (en) 2015-04-16
NZ605444A (en) 2015-06-26
EP2595960B1 (en) 2016-02-24
JP5948326B2 (ja) 2016-07-06
HRP20160540T1 (hr) 2016-06-17
SMT201600171B (it) 2016-07-01
CA2803699C (en) 2016-05-31
JP2017214415A (ja) 2017-12-07
CN103003244A (zh) 2013-03-27
HK1224290A1 (zh) 2017-08-18
US8927575B2 (en) 2015-01-06
SI2595960T1 (sl) 2016-06-30
CN103003244B (zh) 2016-04-20
DK2595960T3 (en) 2016-05-09
HUE028620T2 (en) 2016-12-28
AU2011281381A1 (en) 2013-01-10
WO2012010843A1 (en) 2012-01-26
ES2570135T3 (es) 2016-05-17

Similar Documents

Publication Publication Date Title
HK1243417A1 (zh) 吡啶酮和氮雜吡啶酮化合物及使用方法
HK1224290A1 (zh) 四氫異喹啉衍生物的鹽類和溶劑化物
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
PL3023360T3 (pl) Kapsułka porcjowa i zastosowanie kapsułki porcjowej
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
HK1183014A1 (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
HK1183015A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
AP3917A (en) Subsea anchor
IL220812A0 (en) Compounds and methods
EP2523560A4 (en) CONNECTIONS AND METHODS
EP2594554A4 (en) BIARYLAMID DERIVATIVES BZW. PHARMACEUTICALLY PERMITTED SALT FROM THIS
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
GB201006680D0 (en) Alarm
PL2552910T3 (pl) Nowy polimorf
ZA201400248B (en) Synthesis of cleistainthin a and derivatives thereof
EP2586772A4 (en) ISOQUINOLINE DERIVATIVE
GB201004450D0 (en) Compounds and methods relating thereto
IL225708A0 (en) Methods for the synthesis of scylitol and related compounds
HU1000688D0 (en) Use of trifluoro-phal
TWM389317U (en) Personal effects alarm